Items Tagged ‘risk recurrence’

August 11th, 2014

Large Independent Validation Study Validates Oncotype DX Prostate Cancer Test

By

Genomic Health, Inc. announced positive preliminary results from an additional independent clinical validation study conducted by the Center for Prostate Disease Research (CPDR) demonstrating that the Oncotype DX® Genomic Prostate Score (GPS) predicts multiple clinical endpoints related to disease aggressiveness in men with low- and intermediate-risk prostate cancer.  This study validated the Oncotype DX prostate cancer […]

View full entry

Tags: Early Stage I-II (A-B) Prostate Cancer, News, oncotype, oncotype dx, Prostate Cancer, risk recurrence